(Q36516394)

14 August 2017

1 reference

title

Report by the ACNP Task Force on response and remission in major depressive disorder (English)

1 reference

14 August 2017

Helena Chmura Kraemer

2

object named as

Helena C Kraemer

1 reference

14 August 2017

Philip T Ninan

7

0 references

David Kupfer

10

object named as

David J Kupfer

1 reference

14 August 2017

1

A John Rush

1 reference

14 August 2017

5

Madhukar H Trivedi

1 reference

14 August 2017

8

Michael E Thase

1 reference

14 August 2017

12

Jerrold F Rosenbaum

1 reference

14 August 2017

9

Alan J Gelenberg

1 reference

14 August 2017

4

Maurizio Fava

1 reference

14 August 2017

3

Harold A Sackeim

1 reference

14 August 2017

Ellen Frank

6

1 reference

14 August 2017

Darrel A Regier

11

1 reference

14 August 2017

Oakley Ray

13

1 reference

14 August 2017

Alan F Schatzberg

14

1 reference

14 August 2017

ACNP Task Force

15

1 reference

14 August 2017

language of work or name

English

0 references

publication date

21 June 2006

1 reference

14 August 2017

Neuropsychopharmacology

1 reference

14 August 2017

31

1 reference

14 August 2017

1841-1853

1 reference

14 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301131

14 August 2017

0 references

cites work

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Treatments of depression and the functional capacity to work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Continuation drug therapy for major depressive episodes: how long should it be maintained?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

Outcome predictors for the cognitive behavior treatment of bulimia nervosa: data from a multisite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Gepirone Extended-Release Treatment of Anxious Depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Assessment of reliability in the clinical evaluation of depressive symptoms among multiple investigators in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

ECT in bipolar and unipolar depression: differences in speed of response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Reliability of treadmill exercise testing in older patients with chronic hemiparetic stroke.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Psychosocial predictors of outcome in major depression: a prospective 12-month study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Residual symptoms in depression: an emerging therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Major depressive subtypes and treatment response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The development of study exit criteria for evaluating antimanic compounds.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Defining guilt in depression: a comparison of subjects with major depression, chronic medical illness and healthy controls.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Speed of Response and Remission in Major Depressive Disorder With Acute Electroconvulsive Therapy (ECT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The impact of medical comorbidity on acute treatment in major depressive disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Addressing ethical issues in the psychiatric research literature.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Time to recurrence after recovery from major depressive episodes and its predictors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Sertraline versus imipramine to prevent relapse in chronic depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Mediators and moderators of treatment effects in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The PHQ-9: validity of a brief depression severity measure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Residual symptoms in depressed patients who respond acutely to fluoxetine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Early nonresponse to fluoxetine as a predictor of poor 8-week outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Residual symptoms after partial remission: an important outcome in depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Prevention of relapse in residual depression by cognitive therapy: a controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The definition of remission and its impact on the length of a depressive episode

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Resistance to antidepressant medications and short-term clinical response to ECT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Effectiveness of electroconvulsive therapy in community settings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Medication resistance and clinical response to electroconvulsive therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

When should a trial of fluoxetine for major depression be declared failed?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The Inventory of Depressive Symptomatology (IDS): psychometric properties.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Research issues in the study of difficult-to-treat depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Cost-effectiveness of systematic depression treatment for high utilizers of general medical care

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Outcome definitions and predictors in depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Which depressed patients respond to nefazodone and when?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Partial remission in major depression: a two-phase, 12-month prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Defining remission on the Montgomery-Asberg depression rating scale.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Implications of using different cut-offs on symptom severity scales to define remission from depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301131

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1301131

1 reference

14 August 2017

1 reference